Synthesis of H-bonding probes of α7 nAChR agonist selectivity

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 474-476

  Wang, Jingyi ^a   Papke, Roger L ^b   Horenstein, Nicole A ^a  

^a University of Florida   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Acetylcholine; Agonist; Anabaseine; H bond; Nicotinic; Receptor; Synthesis

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA7; NICOTINIC RECEPTOR; PARTIAL AGONIST; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ALDOL REACTION; ARTICLE; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROGEN BOND; NONHUMAN; XENOPUS;

ANIMALS; HYDROGEN BONDING; MOLECULAR PROBES; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; XENOPUS;

EID: 57749106142     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.044     Document Type: Article

References (25)

1. Dani J.A., and Bertrand D. Ann. Rev. Pharmacol. Toxicol. 47 (2007) 699
2. Romanelli M.N., Gratteri P., Guandalini L., Martini E., Bonaccini C., and Gualtieri F. Chem. Med. Chem. 2 (2007) 746
3. Sharma G., and Vijayaraghavan S. J. Neurobiol. 53 (2002) 524
4. Whiting P.J., and Lindstrom J.M. J. Neurosci. 8 (1988) 3395
5. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., and Kellar K.J. Mol. Pharmacol. 41 (1992) 31
6. Carson R., Craig D., McGuinness B., Johnston J.A., O'Neil F.A., Passmore A.P., and Ritchie C.W. J. Med. Genet. 45 (2008) 244
7. Waldo M.C., Adler L.E., Leonard S., Olincy A., Ross R.G., Harris J.G., and Freedman R. Biol. Psychiatry 47 (2000) 231
8. De Jonge W.J., and Ulloa L. Brit. J. Pharmacol. 151 (2007) 915
9. Franceschini D., Orr-Urtreger A., Yu W., Mackey L.Y., Bond R.A., Armstrong D., Patrick J.W., Beaudet A.L., and De Biasi M. Behav. Brain Res. 113 (2000) 3
10. Damaj M.I., Glassco W., Dukat M., and Martin B.R. J. Pharmacol. Exp. Ther. 291 (1999) 1284
11. Damaj M.I., Kao W., and Martin B.R. J. Pharmcol. Exp. Ther. 307 (2003) 526
12. Papke R.L., Meyer E.M., Lavieri S., Bollampally S.R., Papke T.A.S., Horenstein N.A., Itoh Y., and Papke J.K.P. Neuropharmacology 46 (2004) 1023
13. Leonik F.M., Papke R.L., and Horenstein N.A. Bioorg. Med. Chem. Lett. 17 (2007) 1520
14. Horenstein N.A., Leonik F.M., and Papke R.L. Mol. Pharmacol. 74 (2008) 1496
15. Meyer E.M., Tay E.T., Papke R.L., Meyers C., Huang G.L., and DeFiebre C.M. Brain Res. 768 (1997) 49
16. Kem W.R., Mahnir V.M., Prokai L., Papke R.L., Cao X., LeFrancois S., Wildeboer K., and Prokai-Tatrai K. Mol. Pharmacol. 65 (2004) 56
17. Porter-Papke J., and Soti F. Mol. Pharmacol. 65 (2004) 56
18. Papke, R. L.; Kem, W. R.; Horenstein, N. A., unpublished results.
19. Carson J.R., and Davis N.M. J. Org. Chem. 46 (1981) 839
20. Zoltewicz J.A., and Cruskie Jr. M.P. OPPI BRIEFS 27 (1995) 510
21. Katritzky A.R., Suzuki K., and He H. J. Org. Chem. 67 (2002) 8224
22. Zoltewicz J.A., Prokai-Tatrai K., Bloom L., and Kem W.R. Heterocycles 35 (1993) 171
23. Nielsen A.T., and Houlihan W.J. Org. React. 16 (1968) 1
24. Papke R.L., and Porter-Papke J.K. Br. J. Pharmacol. 137 (2002) 49
25. As pointed out by a reviewer, the impact of pyrrole ring size on the activity of 4a,b relative to 6-membered ring compounds remains an area for investigation.